Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialEmanuel Bührer, Michal Kicinski, Mario Mandala, et al.
Acta Oncologica (Stockholm, Sweden)|April 11, 2023
Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trialsSidsel J Juul, Sára Rossetti, Michal Kicinski, et al.
Discover Oncology|January 29, 2024
Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studiesMaëlle de Ville de Goyet, Michal Kicinski, Stefan Suciu, et al.
Blood|May 8, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michal Kicinski, Corneel Coens, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
JAMA Oncology|January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical TrialAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
NEJM Evidence|February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III MelanomaAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
The Lancet. Oncology|April 15, 2021
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander M M Eggermont, Christian U Blank, Mario Mandalà, et al.
The Lancet. Oncology|May 31, 2025
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Michal Kicinski, Caroline Dutriaux, et al.
Pageof 5